EP
BMRN icon

Eversept Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eversept Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3M Buy
249,607
+41,839
+20% +$2.29M 0.74% 36
2026
Q1 		$11.7M Buy
207,768
+114,020
+122% +$6.65M 0.62% 39
2025
Q4 		$5.57M Sell
93,748
-52,894
-36% -$2.88M 0.28% 67
2025
Q3 		$7.94M Buy
+146,642
New +$8.39M 0.55% 41
2018
Q3 		– Sell
-84,257
Closed -$7.94M – 66
2018
Q2 		$7.94M Buy
84,257
+38,257
+83% +$3.35M 3.63% 8
2018
Q1 		$3.73M Buy
46,000
+300
+0.7% +$25.7K 1.73% 19
2017
Q4 		$4.08M Buy
+45,700
New +$3.97M 2.34% 15

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Eversept Partners's BMRN Position: Q2 2026 in Review

Eversept Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 20% in Q2 2026, buying an estimated $2.29M and bringing the position to 249,607 shares worth $14.3M. The position accounts for 0.74% of the portfolio, ranked #36.

Eversept Partners first reported a position in BMRN in Q4 2017 and has held it in 7 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Eversept Partners held 249,607 shares of BioMarin Pharmaceuticals worth $14.3M as of Q2 2026.
  • Eversept Partners bought 41,839 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.29M.
  • BioMarin Pharmaceuticals made up 0.74% of Eversept Partners's portfolio in Q2 2026, its #36 holding.
  • Eversept Partners first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 7 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.